Syndivia is a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates. Our portfolio includes four unparalleled bioconjugation technologies within the two large domains of bioselective and bioorthogonal chemistry.
|
Syndivia SASCreation: March 2014
|
Syndivia is committed to the development of innovative linker technologies that enhance the performance of Antibody-Drug Conjugates by increasing their plasma stability and specificity of drug release. Syndivia exploits four patented bioconjugation technologies. Its management includes seasoned entrepreuneur backed by a strong team of dedicated professionals.
|
e-Novalys SASCreation: January 2009
|
|
|
Phytodia SASCreation: November 2007
Number of employees: 11 Number of licensed patents: 2 |
Novalix Pharma started as chemical technology based contract research organization. NVX exploited technologies for high throughput reaction discovery/optimization that enabled fast structural scouting and lead otpimisation. Over time the company has expanded its portfolio of technologies in particular in the field of biophysic and label free molecule screening through acquisition of other companies.
|
Novalyst Discovery SASTo date Novalix-Pharma
Following the merging with Alix |
To date Novalix is offering unique technology platforms, such as HTS SPR fragment based hit finding, non-covalent MS screening, MS based rapid chemical optimization, medicinal chemistry expertise, and process development.
Novalix pharma has research facilities located in France and in Spain. It employs 120 peoples among which 45 have PhDs. Its client base spans from large pharma to small biotech in USA, Japan and Europe. |